Corrigendum: Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132 - Cheng, Yezhe; Yuan, Xiaoxi; Tian, Qiang; Huang, Xiuying; Chen, Yang; Pu, Yuzhi; Long, Hu; Xu, Mingyu; Ji, Yafei; Xie, Jia; Tan, Yuping; Zhao, Xi; et al. (Frontiers in Oncology, 2023)